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STUDY PERSONNEL AND CONTACT DETAILS 
 
Sponsor: University of Nottingham 
Contact name Mr Paul Cartledge 
 Head of Research Grants and Contracts 
 Research Innovation Services 
 King’s Meadow Campus 
 Lenton Lane 
 Nottingham 
 NG7 2NR 
 
Chief investigator:  Professor Alan Smyth 
 Phone: 0115 8230611  
 Fax:   
 Email: alan.smyth@nottingham.ac.uk 
 
 
Co-investigators:  Dr Matthew Hurley 
 matthew.hurley@nottingham.ac.uk 
 Dr Andrew Fogarty 
 andrew.fogarty@nottingham.ac.uk 
 Dr Tricia Mckeever 
 tricia.mckeever@nottingham.ac.uk 
 Dr Margaret Rosenfeld 
 margaret.rosenfeld@seattlechildrens.org 
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Title Effect of anti-staphylococcal antibiotic prophylaxis upon 
isolation and colonisation with Staphylococcus aureus, 
Pseudomonas aeruginosa and their resistant variants in cystic 
fibrosis 
Acronym APEC 
Short title Anti-staphylococcal prophylaxis effects in CF 
Chief Investigator Prof Alan Smyth 
Objectives To determine the effects of anti-staphylococcal antibiotic 
prophylaxis upon patients with CF in terms of clinical and 
microbiological outcomes 
Study Configuration Observational cohort longitudinal study  
Setting Cystic Fibrosis Foundation Registry, UK Cystic Fibrosis Trust 
Registry 
2002-2010 
Sample size estimate Assuming the infection prevalence of the UK is 7% and the US 
prevalence is 10% at age 4 years the number needed in each 
cohort would be US (n= 3813) and UK (n= 1271), we have over 
90% power to detect a significant difference (p<0.05) in S. 
aureus infection between the two countries. therefore the 
sample size should be large enough even to detect a small 
difference in bacterial infection 
Number of participants For the 8 year period 2002-2010 we estimate the number of 
newborns diagnosed with CF and included in the registries to 
be –  
Approximately 1880 individuals for the UK CF register  
Approximately 7680 individuals for the US CF register  
Eligibility criteria All patients diagnosed with CF at birth and details registered on 
each of the registries. 
Description of 
interventions 
A comparison in the acquisition of bacteria in those in the UK 
who receive anti-staphylococcal antibiotics and those who do 
not.  Parallel descriptive study of the experience of acquisition 
of these bacteria in the USA. 
Duration of study 8-year observation period. 
Outcome measures Primary outcomes 
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Secondary outcomes 
1. Prevalence of S. aureus, P. aeruginosa, MRSA and MDR-
PA in each cohort  
2. Incidence of first isolation MRSA and MDR-PA 
3. Number of isolates of S. aureus and P. aeruginosa in first 3 
years of life. 
4. To investigate the effect of bacterial colonisation on lung 
function, FEV1 % predicted, BMI/Weight/Height, O2 
requirement, Hospitalisations, Death 
Statistical methods Multivariate Cox regression  for primary analyses 
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Cystic Fibrosis Foundation 
UK Cystic Fibrosis Trust 
Data Analysis Plan 
DMC Data Monitoring Committee 
GCP Good Clinical Practice 
IRB 
MDR-PA 
Institution Review Board 
Multiply drug-resistant Pseudomonas aeruginosa 
NHS National Health Service 
REC Research Ethics Committee 
R&D Research and Development department 
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STUDY BACKGROUND INFORMATION AND RATIONALE 
 
Internationally there is a considerable degree of consensus regarding the standards of care 
patients with cystic fibrosis (CF) should receive1-5.  The prompt and aggressive management 
of infection is central to the strategy of deferring and preventing chronic lung infection2.  Once 
chronic infection is established, eradication is usually not possible and there is a strong 
association between lung infection, morbidity, quality of life and survival6. 
 
The issue of antibiotic prophylaxis for S. aureus remains contentious.  A recent Cochrane 
review7 and the UK CF Trust working group recommends the use of S. aureus prophylaxis.  
However, the concern regarding the possibility of selection of resistant strains of P. 
aeruginosa prompts the Cystic Fibrosis Foundation to recommend refraining from its use. 
 
Recently the US have experienced a rapid increase in the incidence of MRSA in the general 
population, with most of these infections originating in the community.  Infection in patients 
with CF has risen correspondingly. 
 
 
STUDY OBJECTIVES AND PURPOSE 
We wish to determine, whether antibiotic prophylaxis for S. aureus confers a positive or 
negative outcome for patients with CF, in terms of microbiological efficacy (S. aureus 
isolation), complications (P. aeruginosa, MRSA and MDR-PA isolation) and clinical 





(1) Time to first isolation S. aureus,  
(2) Time to first isolation P. aeruginosa 
 
SECONDARY OBJECTIVES 
5. Prevalence of S. aureus, P. aeruginosa, MRSA and MDR-PA in each cohort  
6. Time to first isolation MRSA and MDR-PA 
7. Number of isolates of S. aureus and P. aeruginosa in first 3 years of life. 






Epidemiological observational cohort registry study 
 
STUDY CONFIGURATION 
The primary analysis will utilise the UK CF Trust Registry to compare the time to first 
infection, incidence and prevalence of S. aureus and P. aeruginosa.  The US CFF Registry 
will be used to describe the incidence and time to first infection of S. aureus and P. 
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STUDY MANAGEMENT 
The Chief Investigator has overall responsibility for the study and shall oversee all study 
management. 
 
DURATION OF THE STUDY AND PARTICIPANT INVOLVEMENT 
The study uses data from the two ongoing cohort registries of patients with cystic fibrosis 
from the United Kingdom and the United States.  The analyses will commence when the data 
has been obtained.  Both registries have been designed to track the health of people with 
cystic fibrosis in order to provide health care professionals and researchers information about 
how treatments effect people with CF and to help in the development of guidelines for 
treatment in order to improve health care for these patients.  Patients regularly contribute 
data yearly and during clinical encounters.  
 
The data capture of oral antibiotics was not recorded until 2002 in the CFF trust registry and 
therefore the start date of the study will be in 2002.  Therefore there will be just less than 10 
years of follow-up data in each of the cohorts.   
 
Inclusion criteria 





Patients provide informed consent to the each of the registries prior to their inclusion 





The initial analysis will involve the UK CF Trust Registry to determine the time to first 
infection, prevalence and incidence of S. aureus, P. aeruginosa, MRSA and MDR-PA in 
those that do, and do not receive anti-staphylococcal antibiotic prophylaxis.  The secondary 
analysis will involve a parallel analysis of the US CFF Registry to describe the age at first 
isolation, prevalence and incidence of the organisms of interest.  Direct comparisons 
between the two populations are difficult and so the US analysis will act as a description of 
the experience of these infections in another setting. 
 
For the main analyses, we will use birthdate as the start time and the follow-up time will be 
determined by the time to first acquisition of S. aureus and also time to first acquisition of P. 
aeruginosa.  We will examine the data to determine if the use of antibiotic treatment changes 
the time to acquisition using Cox Proportional Hazard regression model.  The US CFF 
Patient Registry does not capture anti-Staphylococcal prophylaxis specifically but will capture 
treatment of pulmonary exacerbation which, in the setting of Staphylococcus aureus 
infection, will include anti-staph treatment. In the UK sample, we will evaluate the time to 
acquisition in a similar model but with the additional covariate of use of anti-Staphylococcal 
prophylaxis. The proportional hazards assumption will be assessed in both models with 
graphic inspection and assessment of Schoenfeld residuals.  Secondary analyses will 
examine time to acquisition of MRSA and MDR-PA; we will compare the median time to 
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acquisition with 95% CI’s between the US and the UK.  A sensitivity analyses will be 
conducted in those who attain a minimum of 4 cultures a year to determine if the effects are 
the same in this population.   
 
The data will then be examined again using logistic, linear or Cox regression as determined 
by the type of outcome variable to determine how colonisation with S. aureus  bacterial 
infection effect clinical outcomes (longitudinal change in weight percentile, height percentile 
and BMI percentile, lung function, and pulmonary exacerbation) and death.   To assess the 
impact of colonisation on longitudinal measures of growth, nutrition and lung function, mixed 
effects linear regression will be employed.  To assess the impact of S. aureus bacterial 
infection on exacerbation rate, a Poisson regression model will be employed.  This model will 
be examined for over dispersion and if there is evidence of this then we will use a negative 
binomial response  All measure of effects will be investigated for potential confounding 
factors.  All data will be analyzed in Stata or SPSS. 
Sample size and justification  
In 2008 in the UK there were 235 newly diagnosed patients added to the registry8.  Assuming 
a relatively stable accrual, the study population in the UK will be approximately 1880 
individuals.  In the US there were 960 newly diagnosed patients in 20089 resulting in a study 
population of over 7680 individuals.  We will not be undertaking a direct statistical 
comparison between the two Registries and will use all data available. 
 
Limitations 
The background prevalence of MRSA in the USA and the UK differs, illustrated by a 6.3 fold 
excess community acquired MRSA bloodstream rate in the USA10.  As a result, conclusions 
based on the differences between rates of isolation of MRSA in the cohorts will require 
consideration of these background differences. In addition, consideration must be given to 
other confounders including differences in environment (and the background incidence of 
MRSA/MDR-PA), healthcare systems and characteristics of patients in both countries.   
Time to first isolation of the bacteria of interest depends upon respiratory sampling at 
intervals.  Differences between the cohorts in frequency of respiratory sampling could 
influence the time at which a respiratory isolate is identified. 
 
ETHICAL AND REGULATORY ASPECTS 
 
The study will not commence until the Patient Registry Committee of the CFF Registry,  and 
the University of Nottingham Medical School Ethics Committee (IRB) have approved the 
study protocol. 
RECORDS  
No patient identifiable information will be requested from the CFF Registry.  Patient data is 
automatically given a unique identifier (CFF Patient number) at source at the Registry.  Date 
of birth, or age at clinical encounter data will be requested so that age of acquisition of our 
outcomes may be calculated. 
 
DATA PROTECTION  
All study staff and investigators will endeavour to protect the rights of the study’s participants 
to privacy and informed consent, and will adhere to the Data Protection Act, 1998. The CRF 
will only collect the minimum required information for the purposes of the trial. CRFs will be 
held securely, in a locked room, or locked cupboard or cabinet. Access to the information will 
be limited to the trial staff and investigators and any relevant regulatory authorities (see 
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above). Computer held data including the study database will be held securely and password 
protected. All data will be stored on a secure dedicated web server. Access will be restricted 
by user identifiers and passwords (encrypted using a one way encryption method). 
Information about the study in the participant’s medical records / hospital notes will be 
treated confidentially in the same way as all other confidential medical information. 
 




QUALITY ASSURANCE & AUDIT  
 
STUDY CONDUCT 
Study conduct will be subject to systems audit for inclusion of essential documents; 
permissions to conduct the study; CVs of study staff and training received; local document 
control procedures; consent procedures and recruitment logs; adherence to procedures 
defined in the protocol (e.g. inclusion / exclusion criteria,  timeliness of visits); accountability 
of study materials and equipment calibration logs. 
 
STUDY DATA  
Study data and evidence of monitoring and systems audits will be made available for 
inspection as required. 
 
RECORD RETENTION AND ARCHIVING 
In compliance with the ICH/GCP guidelines, regulations and in accordance with the 
University of Nottingham Code of Research Conduct and Research Ethics, the Chief or local 
Principal Investigator will maintain all records and documents regarding the conduct of the 
study. These will be retained for at least 7 years or for longer if required. If the responsible 
investigator is no longer able to maintain the study records, a second person will be 
nominated to take over this responsibility.  
The study documents held by the Chief Investigator on behalf of the Sponsor shall be finally 
archived at secure archive facilities at the University of Nottingham.  This archive shall 
include all study databases and associated meta-data encryption codes. 
 
DISCONTINUATION OF THE TRIAL BY THE SPONSOR  
The Sponsor reserves the right to discontinue this study at any time for failure to meet 
expected enrolment goals, for safety or any other administrative reasons.  The Sponsor shall 
take advice as appropriate in making this decision. 
 
STATEMENT OF CONFIDENTIALITY  
It is the policy of the CFF to protect patient information from unauthorized access or use at all 
times and to assure that this information will only be utilized, transferred, and/or stored in 
sanctioned and approved ways to provide the strictest confidentiality of the patients listed in 
the national Patient Registry database.  No personal identifiable information will be used in 
this study. 
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Results of this study will be disseminated by way of presentation at national and international 
conferences and submission for publication in peer reviewed journals. 
 
The Registry Committee may be consulted on any publications resulting from use of the 
requested data.  This will help assure that the interpretations and conclusions of the authors 
are accurate and consistent with the scientific objectives initially stated in the proposal.  It is 
helpful to the Registry Committee for you to specify all proposed collaborators/co-authors at 
the time of your data request.  
 
When abstracts, exhibits, invited papers or manuscripts are prepared using the CF Patient 
Registry data, the work must carry a credit line to the Cystic Fibrosis Foundation.  The CF 
Foundation requires that no individually identifiable information from the CF Patient Registry 
shall be included in publications, and other written products based on the data request. 
 
When abstracts, poster presentations, or manuscripts are accepted by a scientific 
organization, one copy of said paper, or a suitable description of the exhibit, shall be 
forwarded to the CF Foundation on notice of such acceptance, together with the name of the 
publication or the organization accepting it, and the time and place of the scientific meeting. 
 
At the time manuscripts are submitted for publication, the CF Foundation requires 
simultaneous submission of said manuscripts to the CF Foundation to provide the 
opportunity to review the manuscript, track use of Registry data and to verify the credit line 





Funding source  
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